164 related articles for article (PubMed ID: 36355996)
1. Effects of Zinc Acetate Hydrate Supplementation on Renal Anemia with Hypozincemia in Hemodialysis Patients.
Sato E; Sato S; Degawa M; Ono T; Lu H; Matsumura D; Nomura M; Moriyama N; Amaha M; Nakamura T
Toxins (Basel); 2022 Oct; 14(11):. PubMed ID: 36355996
[TBL] [Abstract][Full Text] [Related]
2. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
[TBL] [Abstract][Full Text] [Related]
3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
4. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.
Hasegawa T; Zhao J; Fuller DS; Bieber B; Zee J; Morgenstern H; Hanafusa N; Nangaku M
Am J Nephrol; 2017; 46(1):11-17. PubMed ID: 28564644
[TBL] [Abstract][Full Text] [Related]
6. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
[TBL] [Abstract][Full Text] [Related]
7. [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
Mpio I; Boumendjel N; Karaaslan H; Arkouche W; Lenz A; Cardozo C; Cardozo J; Pastural-Thaunat M; Fouque D; Silou J; Attaf D; Laville M
Nephrol Ther; 2011 Jul; 7(4):229-36. PubMed ID: 21353659
[TBL] [Abstract][Full Text] [Related]
8. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
9. Changes in erythropoiesis-stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan.
Maruyama Y; Yokoyama K; Higuchi C; Sanaka T; Tanaka Y; Sakai K; Kanno Y; Ryuzaki M; Sakurada T; Hosoya T; Nakayama M;
Ther Apher Dial; 2023 Aug; 27(4):735-741. PubMed ID: 36897071
[TBL] [Abstract][Full Text] [Related]
10. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
11. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
Galle JC; Claes K; Kiss I; Winearls CG; Herlitz H; Guerin A; Di Giulio S; Suranyi MG; Bridges I; Addison J; Farouk M
Nephrol Dial Transplant; 2012 Jun; 27(6):2303-11. PubMed ID: 22140136
[TBL] [Abstract][Full Text] [Related]
12. The influencing factors of the erythropoietin resistance index and its association with all-cause mortality in maintenance hemodialysis patients.
Zhao X; Gan L; Hou FF; Liang X; Chen X; Chen Y; Ni Z; Zuo L
Ren Fail; 2024 Dec; 46(1):2290922. PubMed ID: 38234178
[TBL] [Abstract][Full Text] [Related]
13. Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors.
Takahashi A
Nutrients; 2024 Feb; 16(4):. PubMed ID: 38398842
[TBL] [Abstract][Full Text] [Related]
14. Skeletal muscle mass is associated with erythropoietin response in hemodialysis patients.
Takata T; Mae Y; Yamada K; Taniguchi S; Hamada S; Yamamoto M; Iyama T; Isomoto H
BMC Nephrol; 2021 Apr; 22(1):134. PubMed ID: 33863297
[TBL] [Abstract][Full Text] [Related]
15. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
Biggar P; Ketteler M; Hennemann H; Dömling R
Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
[TBL] [Abstract][Full Text] [Related]
16. Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study.
Okamoto T; Hatakeyama S; Tanaka Y; Imanishi K; Takashima T; Saitoh F; Koie T; Suzuki T; Ohyama C
Clin Exp Nephrol; 2018 Oct; 22(5):1174-1181. PubMed ID: 29600410
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients.
Marcelli D; Bayh I; Merello JI; Ponce P; Heaton A; Kircelli F; Chazot C; Di Benedetto A; Marelli C; Ladanyi E; Kroczak M; Stuard S; Grassmann A; Scatizzi L; Brand K; Canaud B
Kidney Int; 2016 Jul; 90(1):192-202. PubMed ID: 27178833
[TBL] [Abstract][Full Text] [Related]
18. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
[TBL] [Abstract][Full Text] [Related]
19. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
Hahn D; Cody JD; Hodson EM
Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
[TBL] [Abstract][Full Text] [Related]
20. Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.
Choi P; Farouk M; Manamley N; Addison J
Adv Ther; 2013 Nov; 30(11):1007-17. PubMed ID: 24173670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
